Showing 2861-2870 of 5621 results for "".
- Allergan Lifts Earnings Target, Says No Drug Price Hikes This Yearhttps://modernod.com/news/allergan-lifts-earnings-target-says-no-drug-price-hikes-this-year/2479979/Allergan raised its yearly earnings forecast on Thursday thanks to rising sales of mainstay product Botox, and said it did not expect to increase drug prices this year, according to a
- OCT Angiography Predicts Exudation in Macular Degenerationhttps://modernod.com/news/oct-angiography-predicts-exudation-in-macular-degeneration/2479981/Optical coherence tomography (OCT) angiography can help predict which eyes affected by age-related macular degeneration are most likely to develop exudation, research shows, according to a report in Medscape. The new technology can
- EyePoint Pharmaceuticals Announces Presentation of Data Highlighting Yutiq for Posterior Segment Uveitishttps://modernod.com/news/eyepoint-pharmaceuticals-announces-presentation-of-data-highlighting-yutiq-for-posterior-segment-uveitis/2479984/EyePoint Pharmaceuticals announced the presentation of 12-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for noninfectious posterior segment uveitis. The data were presented at the American Society of R
- State Strips Ex-USC Medical School Dean of License, Citing ‘An Appalling Lack of Judgment’https://modernod.com/news/state-strips-ex-usc-medical-school-dean-of-license-citing-an-appalling-lack-of-judgment/2479992/The California state agency that regulates physicians ordered USC’s former medical school dean stripped of his license to practice medicine, citing “an appalling lack of judgment” in his use of drugs an
- Apellis Pharmaceuticals’ APL-2 Receives FDA Fast Track Designation for the Treatment of Patients with GAhttps://modernod.com/news/apellis-pharmaceuticals-apl-2-receives-fast-track-designation-from-fda-for-the-treatment-of-patients-with-geographic-atrophy/2479993/Apellis Pharmaceuticals announced that the FDA has granted fast track designation to the company’s APL-2, a novel inhibitor of complement factor C3 as a next generation monotherapy, for the treatment of patients with geographic atrophy (GA). The FDA’s fast track program faci
- Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-fda-acceptance-of-nda-resubmission-for-dextenza/2480009/Ocular Therapeutix announced that it has received acknowledgement from the FDA that the new drug application (NDA) for Dextenza has been received. Dextenza (dexamethasone insert) 0.4 mg is Ocular Therapeutix’s lead product candidate for the treatment of ocular pain following ophthalmic surgery. T
- CHOP Researchers Develop Highly Specific Predictive Screening Tool for Retinopathy in Premature Infantshttps://modernod.com/news/chop-researchers-develop-highly-specific-predictive-screening-tool-for-retinopathy-in-premature-infants/2480024/A multi-hospital collaboration led by researchers at Children’s Hospital of Philadelphia (CHOP) has found a simple method of determining which premature infants should be screened for retinopathy of prematurity (ROP). The recommendations have the potential t
- EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ for Posterior Segment Uveitis to be Presented at ASRShttps://modernod.com/news/eyepoint-pharmaceuticals-announces-data-highlighting-yutiq-for-posterior-segment-uveitis-to-be-presented-at-asrs/2480032/EyePoint Pharmaceuticals announced that three abstracts supporting the company’s YUTIQ (fluocinolone acetonide intravitreal implant) 3-year micro-insert for noninfectious posterior segment uveitis have been accepted for presentation at the 36th Annual Scientific Meeting of the American Soci
- Ocular Therapeutix Announces NDA Resubmission of Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-nda-resubmission-of-dextenza/2480054/Ocular Therapeutix has announced the resubmission of the company’s new drug application (NDA) to the FDA for its lead product candidate Dextenza (dexamethasone insert) 0.4mg, for the treatment of ocular pain following ophthalmic surgery. The resubmission is intended to address manufacturing defic
- Retinal Thinning Tied to Cognitive Declinehttps://modernod.com/news/retinal-thinning-tied-to-cognitive-decline/2480058/Thinning of the eye’s retinal nerve fiber layer (RNFL) appears to be a strong predictor of cognitive decline, new research shows, according to a report in Medscape. Investigators found healthy individuals with RNFL thinning w